143 related articles for article (PubMed ID: 21830945)
1. Influence of ranibizumab on vascular endothelial growth factor plasma level and endothelial progenitor cell mobilization in age-related macular degeneration patients: safety of intravitreal treatment for vascular homeostasis.
Machalińska A; Paczkowska E; Pabin T; Safranow K; Karczewicz D; Machaliński B
J Ocul Pharmacol Ther; 2011 Oct; 27(5):471-5. PubMed ID: 21830945
[TBL] [Abstract][Full Text] [Related]
2. Endothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration.
Grierson R; Meyer-Rüsenberg B; Kunst F; Berna MJ; Richard G; Thill M
J Ocul Pharmacol Ther; 2013; 29(6):530-8. PubMed ID: 23573802
[TBL] [Abstract][Full Text] [Related]
3. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration.
Papadopoulou DN; Mendrinos E; Mangioris G; Donati G; Pournaras CJ
Ophthalmology; 2009 Sep; 116(9):1755-61. PubMed ID: 19560206
[TBL] [Abstract][Full Text] [Related]
6. Different populations of circulating endothelial cells in patients with age-related macular degeneration: a novel insight into pathogenesis.
Machalinska A; Safranow K; Dziedziejko V; Mozolewska-Piotrowska K; Paczkowska E; Klos P; Pius E; Grymula K; Wiszniewska B; Karczewicz D; Machalinski B
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):93-100. PubMed ID: 20720219
[TBL] [Abstract][Full Text] [Related]
7. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal injection of ranibizumab for treatment of age-related macular degeneration: effects on serum VEGF concentration.
Gu X; Yu X; Dai H
Curr Eye Res; 2014 May; 39(5):518-21. PubMed ID: 24215127
[TBL] [Abstract][Full Text] [Related]
9. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
10. [The impact of locally administrated VEGF inhibitors on vascular homeostasis--controversies concerning safety of intravitreal therapy in AMD patients].
Machalińska A
Klin Oczna; 2012; 114(1):63-7. PubMed ID: 22783749
[TBL] [Abstract][Full Text] [Related]
11. Endothelial progenitor cells and response to ranibizumab in age-related macular degeneration.
Scotti F; Maestroni A; Palini A; Introini U; Setaccioli M; Lorenzi M; Zerbini G
Retina; 2014 Sep; 34(9):1802-10. PubMed ID: 24736462
[TBL] [Abstract][Full Text] [Related]
12. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis].
Michels S; Rosenfeld PJ
Klin Monbl Augenheilkd; 2005 Jun; 222(6):480-4. PubMed ID: 15973626
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.
Schmidt-Erfurth U; Eldem B; Guymer R; Korobelnik JF; Schlingemann RO; Axer-Siegel R; Wiedemann P; Simader C; Gekkieva M; Weichselberger A;
Ophthalmology; 2011 May; 118(5):831-9. PubMed ID: 21146229
[TBL] [Abstract][Full Text] [Related]
15. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration.
Rosenfeld PJ; Schwartz SD; Blumenkranz MS; Miller JW; Haller JA; Reimann JD; Greene WL; Shams N
Ophthalmology; 2005 Jun; 112(6):1048-53. PubMed ID: 15885778
[TBL] [Abstract][Full Text] [Related]
16. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
Wykrota H; Gierek-Lapińska A; Trzciakowski K; Gajdzik-Gajdecka U
Klin Oczna; 2007; 109(10-12):402-9. PubMed ID: 18488382
[TBL] [Abstract][Full Text] [Related]
17. Late outgrowth endothelial progenitor cells in patients with age-related macular degeneration.
Thill M; Strunnikova NV; Berna MJ; Gordiyenko N; Schmid K; Cousins SW; Thompson DJ; Csaky KG
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2696-708. PubMed ID: 18515596
[TBL] [Abstract][Full Text] [Related]
18. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
Lalwani GA; Rosenfeld PJ; Fung AE; Dubovy SR; Michels S; Feuer W; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
[TBL] [Abstract][Full Text] [Related]
19. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
Lowe J; Araujo J; Yang J; Reich M; Oldendorp A; Shiu V; Quarmby V; Lowman H; Lien S; Gaudreault J; Maia M
Exp Eye Res; 2007 Oct; 85(4):425-30. PubMed ID: 17714704
[TBL] [Abstract][Full Text] [Related]
20. Expression of vasohibin, an antiangiogenic factor, in human choroidal neovascular membranes.
Wakusawa R; Abe T; Sato H; Yoshida M; Kunikata H; Sato Y; Nishida K
Am J Ophthalmol; 2008 Aug; 146(2):235-243. PubMed ID: 18486097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
